Aleskandarany MA, Abduljabbar R, Ashankyty I, et al (2016) Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Res Treat 159:215-227.
Altan B, Kaira K, Watanabe A, et al (2018) Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 81:141–153.
Ansari RE, Craze ML, Althobiti M, et al (2020) Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. Br J Cancer 122:94–101.
Araki K, Turner AP, Shaffer VO, et al (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460:108–112.
Baselga J, Campone M, Piccart M, et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529.
Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506-519.
Burstein H J, Curigliano G, Loibl S, et al (2019) Estimating the benefits of therapy for early-stage breast cancer: the st. gallen international consensus guidelines for the Primary Therapy of Early Breast Cancer 2019. Ann Oncol 30:1541–1557.
Dadiani M, Seger D, Kreizman T, et al (2009) Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc. Endocr Relat Cancer 16:819–834.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717.
El Ansari R, Craze ML, Miligy I, et al (2018) The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Res 20:21.
Furuya M, Horiguchi J, Nakajima H, et al (2012) Correlation of L‐type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 103:382–389.
Hare SH, Harvey AJ (2017) mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res 7:383–404.
Hayashi K, Jutabha P, Endou H, et al (2012) c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells. Oncol Rep 28:862–866.
Hayashi K, Anzai N (2017) Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol 9:21–29.
Hickey TE, Selth LA, Chia KM, et al (2021) The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. https://doi.org/10.1038/s41591-020-01168-7
Iacopetta D, Rechoum Y, Fuqua SA (2012) The role of androgen receptor in breast cancer. Drug Discov Today Dis Mech 9:e19-e27.
Ichinoe M, Mikami T, Yoshida T et al (2011) High expression of L‐type amino‐acid transporter 1 (LAT1) in gastric carcinomas: comparison with non‐cancerous lesions. Pathol Int 61:281–289.
Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L‐type amino acid transporter 1 expression in resectable stage I‐III nonsmall cell lung cancer. Br J Cancer 98:742–748.
Kaira K, Oriuchi N, Imai H, et al (2008) l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 99:2380–2386.
Kaira K, Sunose Y, Arakawa K et al (2012) Prognostic significance of L‐type amino‐acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 107:632–638.
Kaira K, Sunose Y, Ohshima Y et al (2013) Clinical significance of L‐type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer 13:482.
Kaira K, Kawashima O, Endoh H et al (2019) Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Hum Pathol 84:142–149.
Kobayashi H, Ishii Y, Takayama T (2005) Expression of L‐type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90:233–238.
Kurozumi S, Yamaguchi Y, Hayashi S et al (2016) Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med 5:1873–1882.
Kurozumi S, Matsumoto H, Hayashi Y et al (2017) Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer 17:354.
Kurozumi S, Matsumoto H, Inoue K et al (2018) Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS One 13:e0201846.
Kurozumi S, Joseph C, Sonbul S et al (2018). Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Res Treat 170:525–533.
Kurozumi S, Matsumoto H, Kurosumi M et al (2019) Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett 17 :2647–2656.
Kurozumi S, Inoue K, Matsumoto H et al (2019) Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep 9:16662.
Kurozumi S, Joseph C, Raafat S et al (2019) Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. Breast Cancer Res Treat 176:63-73.
Land SC, Tee AR (2007) Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282:20534–20543.
Li N, Li Y, Li Z et al (2016) Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 17:E799.
Lieu EL, Nguyen T, Rhyne S, Kim J (2020) Amino acids in cancer. Exp Mol Med; 52:15–30.
Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18:744–757.
Nakanishi K, Ogata S, Matsuo H et al (2007) Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451:681–690.
Nawashiro H, Otani N, Shinomiya N et al (2006) L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119:484–492.
Nawashiro H, Otani N, Shinomiya N et al (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119:484–492.
Ogawa H, Kaira K, Motegi Y et al (2019) Role of amino acid transporter expression as a prognostic marker in patients with surgically resected colorectal cancer. Anticancer Res 39:2535–2543.
Ohshima Y, Kaira K, Yamaguchi A et al (2016) Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Sci 107:1499–1505.
Page DB, Bear H, Prabhakaran S et al (2019) Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 5:34.
Pineda M, Fernández E, Torrents D et al (1999) Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 274:19738–19744.
Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259–271.
Sakata T, Ferdous G, Tsuruta T et al (2009) L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer. Pathol Int 59:7–18.
Shimizu A, Kaira K, Kato M et al (2015) Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Res 25:399–405.
Sun IH, Oh MH, Zhao L et al (2018) mTOR Complex 1 Signaling Regulates the Generation and Function of Central and Effector Foxp3+ Regulatory T Cells. J Immunol 201:481–492.
Toyoda M, Kaira K, Ohshima Y et al (2014) Prognostic significance of amino‐acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br J Cancer 110:2506–2513.
Wang Q, Bailey CG, Ng C et al (2011) Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 71:7525-7536.
Wang Q, Tiffen J, Bailey CG et al (2013) Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst 105:1463-1473.
Yanagida O, Kanai Y, Chairoungdua A et al (2001) Human L‐type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514:291–302.
Yazawa T, Shimizu K, Kaira K et al (2015) Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. Am J Transl Res 7:1126–1139.
Zhao Y, Wang L, Pan J (2015) The role of L-type amino acid transporter 1 in human tumors. Intractable Rare Dis Res. 4:165–169.